<DOC>
	<DOCNO>NCT02135588</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety intrapleural dornase alfa tPA administer patient clinical failure small-bore chest tube persistent pleural effusion malignancy-related loculated effusion improve pleural drainage .</brief_summary>
	<brief_title>Combination Tissue Plasminogen Activator ( Tpa ) Dornase Alfa ( Dnase ) Administration Through Intrapleural Catheters Treatment Loculated Non-Draining Malignant Pleural Effusions</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Clinical failure smallbore chest tube persistent pleural effusion 2 . 18 year age old 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 022 . 4 . Life expectancy ≥ 6 week 5 . Absolute neutrophil count &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 8.0 g/dL 6 . Serum creatinine ≤2.0 time upper limit normal range , total bilirubin ≤ 2.5 mg/dL , AST/ALT ≤ 5 time upper limit normal range 7 . At least 2 day administration chemotherapy 8 . At least 7 day prior major surgery 9 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial . 10 . Patient judge 'medically stable ' primary investigator . 1 . Prior treatment intrapleural fibrinolytic agent 2 . Presence intracranial mass 3 . Traumatic hemorrhagic pleural effusion 4 . Major hemorrhage , coincidental stroke , major trauma 5 . Highrisk systemic bleed 6 . Allergy intolerance dornase alfa 7 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 8 . Serious nonhealing wound , ulcer , bone fracture . 9 . Major surgery , open biopsy significant traumatic injury within seven ( 7 ) day first study drugincluding neurosurgery . 10 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 11 . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement . 12 . Patients pregnant lactating ( female childbearing potential must negative pregnancy test prior participation study ) 13 . Expected survival less six week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>